Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, October 5, 2023
[ Thu, Oct 05th 2023
] - WOPRAI
[ Thu, Oct 05th 2023
] - WOPRAI
[ Thu, Oct 05th 2023
] - WOPRAI
[ Thu, Oct 05th 2023
] - WOPRAI
[ Thu, Oct 05th 2023
] - WOPRAI
[ Thu, Oct 05th 2023
] - WOPRAI
[ Thu, Oct 05th 2023
] - WOPRAI
[ Thu, Oct 05th 2023
] - WOPRAI
[ Thu, Oct 05th 2023
] - WOPRAI
[ Thu, Oct 05th 2023
] - WOPRAI
[ Thu, Oct 05th 2023
] - WOPRAI
[ Thu, Oct 05th 2023
] - WOPRAI
[ Thu, Oct 05th 2023
] - WOPRAI
[ Thu, Oct 05th 2023
] - WOPRAI
[ Thu, Oct 05th 2023
] - WOPRAI
[ Thu, Oct 05th 2023
] - WOPRAI
[ Thu, Oct 05th 2023
] - WOPRAI
[ Thu, Oct 05th 2023
] - WOPRAI
[ Thu, Oct 05th 2023
] - WOPRAI
[ Thu, Oct 05th 2023
] - WOPRAI
[ Thu, Oct 05th 2023
] - WOPRAI
[ Thu, Oct 05th 2023
] - WOPRAI
[ Thu, Oct 05th 2023
] - WOPRAI
[ Thu, Oct 05th 2023
] - WOPRAI
[ Thu, Oct 05th 2023
] - WOPRAI
[ Thu, Oct 05th 2023
] - WOPRAI
[ Thu, Oct 05th 2023
] - WOPRAI
Robyn Karnauskas Downgraded (BTAI) to Hold on, Oct 5th, 2023
Robyn Karnauskas of Truist Securities, Downgraded "BioXcel Therapeutics, Inc." (BTAI) to Hold on, Oct 5th, 2023.
Robyn has made no other calls on BTAI in the last 4 months.
There are 5 other peers that have a rating on BTAI. Out of the 5 peers that are also analyzing BTAI, 3 agree with Robyn's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Graig Suvannavejh of "Mizuho" Reiterated at Hold and Held Target at $4 on, Wednesday, August 23rd, 2023
- Corinne Jenkins of "Goldman Sachs" Maintained at Hold with Decreased Target to $4 on, Tuesday, August 15th, 2023
- Yatin Suneja of "Guggenheim" Downgraded from Strong Buy to Hold on, Monday, July 17th, 2023
These are the ratings of the 2 analyists that currently disagree with Robyn
- Raghuram Selvaraju of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $11 on, Wednesday, September 13th, 2023
- Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $20 on, Tuesday, August 15th, 2023
